Market Cap (In USD)
132.33 Million
Revenue (In USD)
-
Net Income (In USD)
-78.62 Million
Avg. Volume
173.44 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.9-19.298
- PE
- -
- EPS
- -
- Beta Value
- 1.757
- ISIN
- US7133171055
- CUSIP
- 713317105
- CIK
- 1835597
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. James G. McArthur Ph.D.
- Employee Count
- -
- Website
- https://www.pepgen.com
- Ipo Date
- 2022-05-06
- Details
- PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
More Stocks
-
VRSNVeriSign, Inc.
VRSN
-
014915
-
SONOSonos, Inc.
SONO
-
HYSRSunHydrogen, Inc.
HYSR
-
CNQ
-
INCAPIncap Limited
INCAP
-
NAK
-
FPMB